Fact CheckerSign in

NCT05276960CompletedPhase 4

Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF

A Randomized, Double-blind Study of the Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum Vitamin D Levels in Pediatric Patients With Cystic Fibrosis

Source: ClinicalTrials.gov · Last updated 8 Apr 2025

Brief summary (registry, in English)

Cystic fibrosis (CF) is an autosomal recessive disease caused by alterations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, characterized by multisystemic alterations, mainly in the lung, intestine, sweat, and bile ducts. In addition to pulmonary involvement, the presence of exocrine pancreatic insufficiency also increases the risk of survival, as it is associated with malnutrition and deficiency of fat-soluble vitamins, such as vitamin D. Vitamin D, in addition to its role in bone health, in the case of CF patients with chronic inflammation, it has been suggested that many of the cytokines that regulate the inflammatory response contain elements that respond to vitamin D, so vitamin D could play an essential role in the regulation of the inflammatory response in CF, which could favor lung function. However, more than 50% of CF patients present vitamin D insufficiency or deficiency, despite the different schemes suggested for supplementation in different age groups, which suggests that new strategies are needed to normalize vitamin D levels, which will allow us to see its clinical effect on the inflammatory response, by decreasing the number of exacerbations and thus perpetuating or improving lung function, as well as on bone mineral health.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
40 (actual)
First submitted
21 Feb 2022
Start date
22 Jun 2022
Primary completion date
30 Aug 2024
Lead sponsor
Hospital Infantil de Mexico Federico Gomez
NCT number
NCT05276960

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 40
  • From 22 Jun 2022 to the primary completion date, 30 Aug 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Another chronic disease (HIV, cancer, renal failure)

Other

  • 25-OH-VitD levels \< 10 ng/ml or \> 30 ng/ml

Who the study is looking for

  • Cystic Fibrosis

Age in the registry: 5 years to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Infantil de Mexico Federico Gomez
Coordinator of this site? Confirm its status
Mexico CityMexicoUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.